Galapagos gains $3.7M for CF drug

The Flemish agency for Innovation by Science and Technology has handed Galapagos $5.1 million (€3.7 million) grant for preclinical drug work on cystic fibrosis. Galapagos will collaborate on this project with the Center for Human Genetics at the KU Leuven. The company says the funding increases the chances that it will have a preclinical drug candidate in 2013. Release

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.